
Feb 9 (Reuters) -
SPARINGVISION SUCCESSFULLY COMPLETES PRODYGY TRIAL PATIENT DOSING WITH SPVN06, ITS NOVEL NEUROPROTECTIVE GENE THERAPY
SPARINGVISION: INITIAL DATA READOUT FOR NOVEL GENE-AGNOSTIC THERAPY EXPECTED IN 2027
SPARINGVISION: ALL PATIENTS DOSED WITH SPVN06 IN PHASE I/II TRIAL CONTINUE TO DEMONSTRATE A FAVORABLE SAFETY PROFILE
Further company coverage: [ ]